Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Alan Shaw

Gjalt Huisman

Codexis, Inc.

Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.

Janice Chen

Trevor Martin

Jennifer Doudna

Ashley Tehranchi

Lucas Harrington

Mammoth Biosciences

Synonym provides infrastructure for the bioeconomy. The company helps turn breakthroughs in the lab into products on the market by scaling biomanufacturing infrastructure.

Synonym

Ginkgo Bioworks is involved in synthetic biology, providing data-driven R&D services for various industries including agriculture and biopharma. Self-described as the Organism Company.

Ginkgo Bioworks

Grow by Ginkgo

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Synlogic

Empede Capital

General Atlantic

Y Combinator

Bill Gates

T. Rowe Price

Viking Global Investors

Cascade Investment

Illumina

Ginkgo Bioworks, Inc.

This week on Foundry Theory! What is it about biotech R&D that makes collaboration challenging? How can we make it easier?
https://hubs.la/Q02NTygX0

We're excited to welcome Patrick Boyle as an Advisor at SIC. Patrick is currently Ginkgo Bioworks, Inc.'s Chief Scientific Officer, having been at Ginkgo from the earliest days as one of the first full time scientist hires at the company in 2012. As a pioneer in synthetic and computational biology, Patrick brings unparalleled expertise to our extended network. His experience in developing Ginkgo’s codebase and driving customer-focused business development is a powerful addition to our firm’s toolkit. Welcome Patrick!

https://lnkd.in/eZjsX4ZQ

I tried to go a bit sassy and provocative in this week's video, asking "which type of nerds are the coolest?"

My professional opinion: it's the bio nerds

We're #hiring a new Director, Infrastructure Enablement in United States. Apply today or share this post with your network.

Ginkgo is pleased to announce Max Breet, Director of Business Development EMEA, will be joined by other industry experts at this year's upcoming GLOBSEC Forum to discuss the growing need for robust biosecurity infrastructure and what it will take to get us there!

#GLOBSEC2024 #GLOBSECPRAGUE

Metric
Company Name	Ginkgo Bioworks Holdings, Inc.	Codexis, Inc.	Mammoth Biosciences	Synonym
Symbol	DNA	CDXS
MSH ID	COM:GINKGOBIOWORKS	COM:CODEXIS	BIO:MAMMOTH	BIO:SYNONYM
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Technology
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage	Grant		Series D
Employee Count	1.22K	174	185	27
Website	ginkgobioworks.com	codexis.com	mammoth.bio	synonym.bio
LinkedIn	ginkgo-bioworks	codexis	mammothbio	synonymbio
Founders

Metric
Market Cap	725.64M	204.62M
Enterprise Value
Monthly Web Traffic	20.69K	3.96K	6.85K
Web Traffic Growth	-0.17	1.51	-0.30
Valuation
Raised Capital		40M	150M

Metric
Revenue	251.46M	70.14M
Revenue (LTM)
Revenue (NTM)
Gross Profit	142.64M	51.82M
EBITDA	-600.68M	-44.88M
Operating Income	-672.23M	-54.80M
Net Income	-892.87M	-76.24M
EPS	-0.46	-1.12
Diluted EPS	-0.46	-1.12
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.75	0.81
Operating Profit Margin	-3.34	-0.76
EBITDA Margin	-2.39	-0.64
Net Profit Margin	-3.55	-0.88
Return on Equity	-0.65	-0.68
Return on Assets	-0.54	-0.44
Return on Capital Employed	-0.51	3.80

COM:GINKGOBIOWORKS

Ginkgo Bioworks

Last Close

6.59

22/11 21:00

Market Cap

725.64M

Beta: -

Volume Today

129

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.78	-2.27
P/B Ratio	1.90	2.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	93.70	4.12
EV Multiple	-1.34	-4.84

Metric
Days Sales Outstanding	73.17	94.23
Days Payables Outstanding	50.57	61.44
Days Inventory Outstanding	0.27	69.87
Operating Cycle	46.33	173.57
Cash Conversion Cycle	-7.39	45.90
Asset Turnover	0.15	5.20

Metric
Operating Cash Flow	-295.50M	-52.64M
Free Cash Flow	-336.30M	-57.06M
Cash Flow to Debt	-0.63	-1.19
Operating Cash Flow/Sales	-1.14	-0.69
Free Cash Flow Yield	-0.16	-0.12

Metric
Cash & Equivalents	948.86M	65.64M
Accounts Receivable	50.07M	20.25M
Inventory	46K	2.69M
Goodwill	49.24M	2.46M
Debt to Capitalization	0.35	0.35
Debt to Assets	0.20	0.13
Current Ratio	6.78	2.68
Quick Ratio	5.98	3.63

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.94	0.11
R&D to Revenue	2.05	0.91
SG&A to Revenue	1.32